Early Benefit from Structured Care with Atorvastatin in Patients with Coronary Heart Disease and Diabetes Mellitus

Angiology

Volumn 54, Issue 6, 2003, Pages 679-690

  Athyros, Vasilios G ^a,d   Papageorgiou, Athanasios A ^a   Symeonidis, Athanasios N ^b   Didangelos, Triandafillos P ^a   Pehlivanidis, Anthimos N ^a   Bouloukos, Vasilios I ^a   Mikhailidis, Dimitrios P ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Greek Soc of General Practitioners   (Greece)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIABETES MELLITUS; EVALUATION; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 0344442802     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970305400607     Document Type: Article

References (46)

1. American Diabetes Association: Position Statement: Management of dyslipidemia in adults with diabetes. Diabetes Care 25:S74-S77, 2002.
2. American Diabetes Association: Management of dyslipidemia in adults with diabetes. Diabetes Care 24:S58-S61, 2001.
3. National Cholesterol Education Program: Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 89:1333-1445, 1994.
4. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001.
5. Pitsavos CE, Toutouzas PK: Cardiovascular Risk Factor Profile in Greece: Results from the CARDIO2000 and ATTICA epidemiological studies. Curr Med Res Opin 18:277-283, 2002.
6. Athyros VG, Papageorgiou AA, Mercouris BR, et al: Treatment with atorvastatin to the National Cholesterol Educational Program goals versus usual care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 18:220-228, 2002.
7. Jones P, Kafonek S, Laurora I, et al: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81:582-587, 1998.
8. Andrews TC, Ballantyne CM, Hsia JA, et al: Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 111:185-191, 2001.
9. Forrester JS, Bairey-Merz CN, Sanjay Kaul S: The aggressive low-density lipoprotein lowering controversy. J Am Col Cardiol 36:1419-1425, 2000.
10. Genest J Jr, Cohn JS: Clustering of cardiovascular risk factors: Targeting high-risk individuals. Am J Cardiol 76(suppl A):8S-205, 1995.
11. Ballantyne CM, Andrews TC, Hsia JA, et al, for the ACCESS Study Group. Atorvastatin Comparative Cholesterol Efficacy and Safety (the ACCESS) Study. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: Effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 88:265-259, 2001.
12. Smilde TJ, van Wissen S, Wollersheim H, et al: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial. Lancet 357:577-581, 2001.
13. Keys A, Menotti A, Karvonen MJ, et al: The diet and 15-year death rate in the seven countries study. Am J Epidemiol 124:903-915, 1986.
14. Ruof J, Klein G, Marz W, et al: Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: The gap between treatment guidelines and real life treatment patterns. Prev Med 35:48-53, 2002.
15. Fonarow GC, French WJ, Parsons LS, et al: Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: Data from the National Registry of Myocardial Infarction 3. Circulation 103:38-44, 2001.
16. Kinn JW, Brown AS: Cardiovascular risk management in clinical practice: The Midwest Heart Specialists experience. Am J Cardiol 89(5A):23C-29C, 2002.
17. Scandinavian Simvastatin Survival Study (4S) Group: Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease. Lancet 344:1383-1389, 1994.
18. Sacks FM, Pfeffer MA, Moye LA, et al: CARE Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009, 1996.
19. Long-term Intervention with Pravastatin Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357, 1998.
20. Pyörälä K, Pedersen TR, Kjekshus J, et al: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620, 1997.
21. Haffner SM, Alexander CM, Cook TJ, et al: Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 159:2661-2667, 1999.
22. Colhoun HM, Thomason MJ, Mackness MI, et al and the CARDS Investigators: Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabetic Med 19:201-211, 2002.
23. Sever PS, Dahlöf B, Poulter N, et al, for the ASCOT Investigators. Lancet 361:1149-1158, 2003.
24. Sacco RL, Benjamin EJ, Broderick JP, et al: American Heart Association Prevention Conference IV: Prevention and rehabilitation of stroke: Risk factors. Stroke 28:1507-1517, 1997.
25. National Heart, Lung, and Blood Institute: Morbidity and Mortality: 2000 Chart Book. Bethesda, MD. National Center for Health Statistics; 2000.
26. White HD, Simes RJ, Anderson NE, et al: Pravastatin therapy and the risk of stroke. N Engl J Med 343:317-326, 2000.
27. Blauw GJ, Lagaay AM, Smelt AH, et al: Stroke, statins, and cholesterol: A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 28:946-950, 1997.
28. Crouse JR III, Byington RP, Hoen HM, et al: Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 157:1305-1310, 1997.
29. Davis M, Atwal AS, Nair DR, et al: The effect of short-term lipid lowering with atorvastatin on carotid artery intima media thickness in patients with peripheral vascular disease: A pilot study. Curr Med Res Opin 16:198-204, 2000.
30. Youssef F, Seifalian AM, Jagroop A, et al: The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT). Eur J Vasc Endovasc Surg 23:358-364, 2002.
31. Schwartz GG, Olsson AG, Ezekowitz MD, et al: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 285:1711-1718, 2001.
32. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: A randomised placebo-controlled trial. Lancet 361:2005-2016, 2003.
33. Athyros VG, Papageorgiou AA, Elisaf M, et al: The statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 19:615-617, 2003.
34. Athyros VG, Papageorgiou AA, Athyrou VV, et al: Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 25:1198-1202, 2002.
35. Kakafika A, Liamis G, Elisaf M, et al: Effect of atorvastatin on serum creatinine levels. Curr Med Res Opin 17:230-231, 2001.
36. Elisaf M, Mikhailidis DP: Statins and renal function. Angiology 53:493-502, 2002.
37. Tsiara S, Elisaf M, Mikhailidis DP: Early vascular benefits of statin therapy. Curr Med Res Opin 19:540-556, 2003.
38. Youssef F, Gupta P, Seifalian AM, et al: The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology (in press).
39. Kaplan RC, Heckbert SR, Furberg CD, et al: Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction. J Clin Epidemiol 55:654-664, 2002.
40. Bickel C, Rupprecht HJ, Blankenberg S, et al: Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 89:12-17, 2002.
41. Fang J, Alderman MH: Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 283:2404-2410, 2000.
42. Hay JW, Yu WM, Ashraf T: Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. Pharmacoeconomics 15:47-74, 1999.
43. Jonsson B, Cook JR, Pedersen TR: The cost-effectiveness of lipid lowering in patients with diabetes: Results from the 4S trial. Diabetologia 42:1293-1301, 1999.
44. Herman WH, Alexander CM, Cook JR, et al: Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. Diabetes Care 22:1771-1778; 1999.
45. Mikhailidis DP, Wierzbicki AS: Editorial Comment: The GREek Atorvastatin and Coronary-heart disease Evaluation (GREACE) study. Curr Med Res Opin 18:215-219, 2002.
46. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al: Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 18:499-502, 2002.